GSK plc (LSE/NYSE: GSK) said the U.S. Food and Drug Administration has approved Exdensur, a twice-yearly biologic treatment ...
An asthma treatment that only requires patients to have two jabs a year to prevent life-threatening attacks will be available ...
The FDA has approved Exdensur (depemokimab-ulaa) as an add-on maintenance treatment for people with severe asthma.
Editor's note: Dr. Edith Bracho-Sanchez is a primary care pediatrician, director of pediatric telemedicine and assistant professor of pediatrics at Columbia University Irving Medical Center. Flovent, ...
Indiana University School of Medicine researchers are taking a closer look at how young patients respond to biologic ...
Six months after GSK stopped making a popular inhaler, pediatric patients with asthma still struggle to find alternative medications while urgent cares and hospitals contend with a rise in ...
Prices for care at hospital trauma centers vary across hospitals; drug shortages reached a record high during the first quarter of 2024; although 3 of the biggest makers of asthma inhalers pledged to ...
From Philly and the Pa. suburbs to South Jersey and Delaware, what would you like WHYY News to cover? Let us know! When Media-resident Jacqueline Vakil needed a refill in January for Flovent, her ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback